On November 9, Dr. Fu Chengbin, President of Guangzhou Institute of Digital Therapy for Chronic Diseases, Teacher Xu Teng and chief physician Zhang Rui of Liaoning Cancer Hospital visited Shenzhen Cell Valley. Professor Shi Yuanyuan, chairman of Shenzhen Cell Valley, Professor Wang Jianxun, chief scientist, Tang Xiaomeng, deputy general manager, and Sun Rui, Director of Marketing Department, warmly received and carried out discussions and exchanges to discuss the direction of development together.

Under the leadership of Chairman Professor Shi Yuanyuan, President Fu Chengbin and his delegation visited the smart exhibition hall and learned about the company's development history, business segments, scientific research and innovation platform system and other basic information, and then went into the front line of production and research and development to closely experience the standardized, specialized and advanced GMP grade cell and carrier production process.

At the symposium, Professor Shi Yuanyuan analyzed the status quo of the pharmaceutical research and development service industry and introduced the comprehensive one-stop innovation service platform from basic research to industrial production built by Shenzhen Cell Valley in a short period of time, the characteristics of the core technology - retroviral vector and the feedback of customers of leading hospitals. President Fu Chengbin affirmed and recognized the professionalism and authority of Shenzhen Cell Valley, emphasizing that it is necessary to effectively solve the needs of grassroots doctors and patients, optimize precision treatment programs, and jointly explore new medical channels enabled by science and technology. As a CRO/CDMO service provider of innovative cell and gene therapy, Shenzhen Cell Valley will rely on cost advantages and efficiency advantages, start from the pain points of customers, analyze the needs, improve the research and development ability of cell and gene therapy, accelerate the transformation and application of scientific research results, and drive the whole industrial chain upstream and downstream scientific research institutions, hospitals, pharmaceutical companies, universities, etc., to integrate innovation and promote the development of the industry. Breakthroughs in the development of biomedicine.

During this visit and exchange, the two sides reached a consensus that they will give full play to their respective advantages and cooperate with major medical institutions to carry out strategic cooperation in the fields of production, research, management and treatment of chronic disease and cancer patients, establish cell research and clinical "production, learning, research, transfer, innovation and use" cooperation and cell upstream and downstream industry chain cooperation platform, and work together. To realize the integration of resources, complementary advantages, mutual benefit and win-win situation, and inject new strength into the development of China's medical industry.